Phosphoserine Dependant Assembly of Signaling complexes

信号复合物的磷酸丝氨酸依赖性组装

基本信息

  • 批准号:
    7283024
  • 负责人:
  • 金额:
    $ 28.22万
  • 依托单位:
  • 依托单位国家:
    美国
  • 项目类别:
  • 财政年份:
    2000
  • 资助国家:
    美国
  • 起止时间:
    2000-09-01 至 2009-08-31
  • 项目状态:
    已结题

项目摘要

DESCRIPTION (provided by applicant): Phosphoserine/threonine-binding domains play critical roles in controlling multiple aspects of cell proliferation, including cell cycle progression and the cellular response to DNA damage. The current list of pSer/pThr-binding domains includes 14-3-3 proteins, FHA domains, WW domains, WD40 repeats of F-box proteins, tandem BRCT domains and the Polo-box domains of Polo-like kinases. The long-term goal of our laboratory is to identify and characterize these domains with a focus on identifying their physiological ligands, determining the structural basis for their pSer/Thr-motif recognition, and elucidating the molecular basis for their functions in cell cycle control within complex protein kinase signaling networks. Polo-like kinases are essential during multiple stages of the eukaryotic cell cycle, including many of the events that occur during M-phase, as well as in the DNA damage response. Despite their importance, details about how Polo-like kinase activity is regulated, and the identity of their substrates are poorly understood. In this proposal we use a combination of biochemical, structural and cell biological techniques to determine the function of the invariant pSer/pThr-binding Polo-box domain in regulating the activation of, and the substrate selection and phosphorylation by Polo-like kinases. In the process, we will identify many new Polo-like kinase ligands and substrates that may be responsible for the pleiotropic role these kinases play in the cell. Since Polo-like kinases are upregulated in many types of human cancer, and since their experimental down-regulation results in decreased cell proliferation and tumor regression, the results of our experiments should determine whether the Polo-box domain is a good target for novel anti-cancer drug design.
描述(由申请人提供):

项目成果

期刊论文数量(36)
专著数量(0)
科研奖励数量(0)
会议论文数量(0)
专利数量(0)
Cytokine-induced signaling networks prioritize dynamic range over signal strength.
  • DOI:
    10.1016/j.cell.2008.08.034
  • 发表时间:
    2008-10-17
  • 期刊:
  • 影响因子:
    64.5
  • 作者:
    Janes KA;Reinhardt HC;Yaffe MB
  • 通讯作者:
    Yaffe MB
Linear motif atlas for phosphorylation-dependent signaling.
  • DOI:
    10.1126/scisignal.1159433
  • 发表时间:
    2008-09-02
  • 期刊:
  • 影响因子:
    7.3
  • 作者:
    Miller ML;Jensen LJ;Diella F;Jørgensen C;Tinti M;Li L;Hsiung M;Parker SA;Bordeaux J;Sicheritz-Ponten T;Olhovsky M;Pasculescu A;Alexander J;Knapp S;Blom N;Bork P;Li S;Cesareni G;Pawson T;Turk BE;Yaffe MB;Brunak S;Linding R
  • 通讯作者:
    Linding R
Kinases that control the cell cycle in response to DNA damage: Chk1, Chk2, and MK2.
  • DOI:
    10.1016/j.ceb.2009.01.018
  • 发表时间:
    2009-04
  • 期刊:
  • 影响因子:
    7.5
  • 作者:
    Reinhardt HC;Yaffe MB
  • 通讯作者:
    Yaffe MB
Peptoid-Peptide hybrid ligands targeting the polo box domain of polo-like kinase 1.
NetworKIN: a resource for exploring cellular phosphorylation networks.
  • DOI:
    10.1093/nar/gkm902
  • 发表时间:
    2008-01
  • 期刊:
  • 影响因子:
    14.9
  • 作者:
    Linding R;Jensen LJ;Pasculescu A;Olhovsky M;Colwill K;Bork P;Yaffe MB;Pawson T
  • 通讯作者:
    Pawson T
{{ item.title }}
{{ item.translation_title }}
  • DOI:
    {{ item.doi }}
  • 发表时间:
    {{ item.publish_year }}
  • 期刊:
  • 影响因子:
    {{ item.factor }}
  • 作者:
    {{ item.authors }}
  • 通讯作者:
    {{ item.author }}

数据更新时间:{{ journalArticles.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ monograph.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ sciAawards.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ conferencePapers.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ patent.updateTime }}

MICHAEL B YAFFE其他文献

PLASMINOGEN DEFICIENCY OF PLEURAL FLUID DUE TO NEUTROPHIL INFLAMMATORY PROTEASE DEGREDATION IN EMPYEMA PATIENTS: A CAUSE OF INTRAPLEURAL LYTIC FAILURE?
  • DOI:
    10.1016/j.chest.2023.07.4196
  • 发表时间:
    2023-10-01
  • 期刊:
  • 影响因子:
  • 作者:
    CHRISTOPHER D BARRETT;PETER MOORE;HUNTER B MOORE;ERNEST E MOORE;JAMES G CHANDLER;ANGELA SAUAIA;KEELY BUESING;DANIEL HERSHBERGER;IVOR S DOUGLAS;ANGEL AUGUSTO DR PEREZ-CALATAYUD;MICHAEL B YAFFE
  • 通讯作者:
    MICHAEL B YAFFE

MICHAEL B YAFFE的其他文献

{{ item.title }}
{{ item.translation_title }}
  • DOI:
    {{ item.doi }}
  • 发表时间:
    {{ item.publish_year }}
  • 期刊:
  • 影响因子:
    {{ item.factor }}
  • 作者:
    {{ item.authors }}
  • 通讯作者:
    {{ item.author }}

{{ truncateString('MICHAEL B YAFFE', 18)}}的其他基金

Protein Kinase Signaling in the Genotoxic Stress Response
基因毒性应激反应中的蛋白激酶信号转导
  • 批准号:
    9975171
  • 财政年份:
    2017
  • 资助金额:
    $ 28.22万
  • 项目类别:
Protein Kinase Signaling in the Genotoxic Stress Response
基因毒性应激反应中的蛋白激酶信号转导
  • 批准号:
    10219250
  • 财政年份:
    2017
  • 资助金额:
    $ 28.22万
  • 项目类别:
Protein Kinase Signaling in the Genotoxic Stress Response
基因毒性应激反应中的蛋白激酶信号转导
  • 批准号:
    10664948
  • 财政年份:
    2017
  • 资助金额:
    $ 28.22万
  • 项目类别:
Protein Kinase Signaling in the Genotoxic Stress Response
基因毒性应激反应中的蛋白激酶信号转导
  • 批准号:
    9752562
  • 财政年份:
    2017
  • 资助金额:
    $ 28.22万
  • 项目类别:
Protein Kinase Signaling in the Genotoxic Stress Response
基因毒性应激反应中的蛋白激酶信号转导
  • 批准号:
    10445249
  • 财政年份:
    2017
  • 资助金额:
    $ 28.22万
  • 项目类别:
Biopolymers & Proteomics
生物聚合物
  • 批准号:
    9149768
  • 财政年份:
    2015
  • 资助金额:
    $ 28.22万
  • 项目类别:
Phospho-Binding Ligands and Substrates of BRCA1
BRCA1 的磷酸结合配体和底物
  • 批准号:
    8413981
  • 财政年份:
    2012
  • 资助金额:
    $ 28.22万
  • 项目类别:
Phospho-Binding Ligands and Substrates of BRCA1
BRCA1 的磷酸结合配体和底物
  • 批准号:
    8502497
  • 财政年份:
    2012
  • 资助金额:
    $ 28.22万
  • 项目类别:
Biopolymers & Proteomics
生物聚合物
  • 批准号:
    8181146
  • 财政年份:
    2010
  • 资助金额:
    $ 28.22万
  • 项目类别:
DNA Damage Networks
DNA损伤网络
  • 批准号:
    8181035
  • 财政年份:
    2010
  • 资助金额:
    $ 28.22万
  • 项目类别:

相似海外基金

Delays in Acquisition of Oral Antineoplastic Agents
口服抗肿瘤药物的获取延迟
  • 批准号:
    9975367
  • 财政年份:
    2020
  • 资助金额:
    $ 28.22万
  • 项目类别:
Eliminate the difficulty of venous puncture in patients receiving antineoplastic agents - Development of a new strategy for the prevention of induration-
消除接受抗肿瘤药物的患者静脉穿刺的困难 - 制定预防硬结的新策略 -
  • 批准号:
    16K11932
  • 财政年份:
    2016
  • 资助金额:
    $ 28.22万
  • 项目类别:
    Grant-in-Aid for Scientific Research (C)
Molecular mechanisms of the antineoplastic agents inhibiting DNA replication and their applications to cancer patient treatmen
抗肿瘤药物抑制DNA复制的分子机制及其在癌症患者治疗中的应用
  • 批准号:
    19591274
  • 财政年份:
    2007
  • 资助金额:
    $ 28.22万
  • 项目类别:
    Grant-in-Aid for Scientific Research (C)
PNET EXPERIMENTAL THERAPEUTICS--ANTINEOPLASTIC AGENTS AND TREATMENT DELIVERY
PNET 实验治疗——抗肿瘤药物和治疗实施
  • 批准号:
    6346309
  • 财政年份:
    2000
  • 资助金额:
    $ 28.22万
  • 项目类别:
TRAINING IN PHARMACOLOGY OF ANTINEOPLASTIC AGENTS
抗肿瘤药物药理学培训
  • 批准号:
    2720213
  • 财政年份:
    1999
  • 资助金额:
    $ 28.22万
  • 项目类别:
TRAINING IN PHARMACOLOGY OF ANTINEOPLASTIC AGENTS
抗肿瘤药物药理学培训
  • 批准号:
    6513197
  • 财政年份:
    1999
  • 资助金额:
    $ 28.22万
  • 项目类别:
Training in Pharmacology of Antineoplastic Agents
抗肿瘤药物药理学培训
  • 批准号:
    7101017
  • 财政年份:
    1999
  • 资助金额:
    $ 28.22万
  • 项目类别:
Training in Pharmacology of Antineoplastic Agents
抗肿瘤药物药理学培训
  • 批准号:
    6894842
  • 财政年份:
    1999
  • 资助金额:
    $ 28.22万
  • 项目类别:
TYROSINE KINASE INHIBITORS AS ANTINEOPLASTIC AGENTS
酪氨酸激酶抑制剂作为抗肿瘤剂
  • 批准号:
    2885074
  • 财政年份:
    1999
  • 资助金额:
    $ 28.22万
  • 项目类别:
TYROSINE KINASE INHIBITORS AS ANTINEOPLASTIC AGENTS
酪氨酸激酶抑制剂作为抗肿瘤剂
  • 批准号:
    6174221
  • 财政年份:
    1999
  • 资助金额:
    $ 28.22万
  • 项目类别:
{{ showInfoDetail.title }}

作者:{{ showInfoDetail.author }}

知道了